Vol.171 éºäŒåå€ç°ã調ã¹ãã¿ã€ãã³ã°ã¯æ©ããã°æ©ãæ¹ãè¯ãïŒ
æ¯èŒçæããªæ¥ã®å€ãä»å¬ã§ãããå
ææ«ã¯é¢è¥¿åºåŒµã§æ»è³çã®å€§éªã«ééããã³ã£ããããŸããã
ãã®ææã®é¢è¥¿ãšæ±äº¬ã®åŸåŸ©ã¯é·å¹Žãã£ãŠããŠãããé¢ã¶åä»è¿ã®âéªåœã¶ãâã¯ããç¥ã£ãŠããŸããããããããŸã§ã®å¢ãã§éªãç©ãã£ãŠããã®ãèŠãã®ã¯åããŠã§ããã
ãã¥ãŒã¹ã«ãªã£ãåç¥é«ééè·¯ã®ç«ã¡åŸçããããããéè»¢ã®æ°å¹¹ç·ããç®ã®åœããã«ããŠãããã¯ãããããšã ãšæã£ããã®ã§ãã
å
æ¥ã®é¢æ±å°æ¹ã®å€§éªã®æ¥ããæ±äº¬ã®äžè¬éãå€§æžæ»ã«ãªã£ãŠããŸãããã倧éªãäºæ³ãããæ¥ã¯ããšã«ããè»ã§åºãããããšã¯æ§ããæ¹ãè¯ãã§ããã
äžã€ããç¥ããã§ãã
ãã€ã·ã¥ã©ã³ç®èãããããªãªãŒã¹ããŸããã
ããã§ãä¹³ãããè¡æ¶²ããã婊人ç§ãããèºããã«ç¶ããïŒã€ç®ã®é åã§ããåŒãç¶ããã«ããŒé åãåºããŠåããŸã!!
ââââââââââââââââââââââââââââââ
ãèšäº1ã éºäŒåå€ç°ã調ã¹ãã¿ã€ãã³ã°ã¯æ©ããã°æ©ãæ¹ãè¯ãïŒ
âââââââââââââââââââââââââââââââââââ
éºäŒåããã«æ€æ»ã®æçŸ©ã«ã€ããŠã¯ããã®ã¡ã«ãã¬ã§äœåºŠãåãäžããŠããŸããã
æ¥æ¬ã®ä¿éºå¶åºŠã®çŸç¶ãããããšãéºäŒåããã«æ€æ»ãä¿éºé©çšãããã®ã¯ãåºåœ¢ããã«ãããŠãä»ã®æšæºçãªæ²»çææ®µããªããªã£ã段éãã§ãïŒåéããã§ãã
ããããªãããããã§æ¬åœã«è¯ãã®ã§ããããïŒ
éºäŒåå€ç°ãããæ©æã®æ®µéã§ããã£ãããããã«å¯Ÿå¿ããæ²»çãå
ã«è¡ãããšãå¯èœã«ãªããŸãã
ãã¡ãããåŸããããã£ãŠãéºäŒåå€ç°ã«å¯Ÿå¿ããæ²»çã¯ã§ããããã§ãããããã«ãã£ãŠçããæ²»çã®é çªã®éãããæ²»çæçžŸã«åœ±é¿ããªããšèšããã§ããããïŒ
ãã®ç¹ã«é¢ããéåžžã«ç€ºåã®ããç ç©¶çµæãåºãŠããŸããã
ãâ âCompromised Outcomes in Stage IV NonâSmall-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Dataâ
ãããã·ã³ãããŒãŒé»å®³å€ãªãã§åææ²»çããããæ²»çå¯èœãªå€ç°ãæããã¹ããŒãžIVã®éå°çްèèºããã«ãããäºåŸã®æªåïŒãªã¢ã«ã¯ãŒã«ãããŒã¿ã®åŸæ¹èŠçè§£æãïŒJournal of Clinical OncologyïŒ
éå°çްèèºããã¯ããããåŒãèµ·ããéºäŒåå€ç°ã®çš®é¡ãæãæ°å€ãèŠã€ãã£ãŠããããã§ãããã«å¯Ÿå¿ããååæšçè¬ïŒããã·ã³ãããŒãŒé»å®³å€ïŒãæ°å€ãéçºãããŠããŸãã
ãã®äžã§ãæ©æã«èª¿ã¹ãŠéºäŒåå€ç°ã«å¯Ÿå¿ããæ²»çãåããŠãã人ãšãæåã¯å¥ã®æ²»çãããŠåŸããéºäŒåå€ç°ã«å¯Ÿå¿ããæ²»çãåããŠããäººãæ··åšããŠããŸãã
ããã§ãå
šç±³ã®1000ãè¶
ããå»çæ©é¢ããéå»ã®æ²»çããŒã¿ãéããæ²»çå¯èœãšèããããéºäŒåå€ç°ïŒEGFR, ALK, ROS1, BRAF, MET, RET, HER2, NTRK1/2/3ïŒãèŠã€ãã£ãã¹ããŒãžïŒã®éå°çްèèºããæ£è
510åããæ¬¡ã®ïŒçŸ€ã«åããŠåæããã®ããäžèšã®ç ç©¶ã§ãã
ã»ã°ã«ãŒãAïŒéºäŒåå€ç°ã®çµæã倿ããŠãããé©åããååæšçè¬ã§æ²»çéå§ãã矀ïŒ379åïŒ
ã»ã°ã«ãŒãBïŒéºäŒåå€ç°ã®çµæã倿ããåã«ãååŠçæ³ãããã¯å
ç«ãã§ãã¯ãã€ã³ãé»å®³å€ã®æ²»çãéå§ãã35æ¥ä»¥å
ã«ååæšçè¬ã®æ²»çã«ã¹ã€ãããã矀ïŒ47åïŒ
ã»ã°ã«ãŒãCïŒéºäŒåå€ç°ã®çµæã倿ããåã«ãååŠçæ³ãããã¯å
ç«ãã§ãã¯ãã€ã³ãé»å®³å€ã®æ²»çãéå§ãã35æ¥ä»¥å
ã«ååæšçè¬ã®æ²»çã«ã¹ã€ããããªãã£ã矀ïŒ84åïŒ
æ¬¡ã®æ²»çãããã¯äº¡ããªããããŸã§ã®æéïŒTTNTïŒãšãå
šçåæéïŒOSïŒãæ¯èŒããŠã¿ããšããã
ïŒæ¬¡ã®æ²»çãããã¯äº¡ããªããããŸã§ã®æéïŒTTNTïŒïŒ
ã»ã°ã«ãŒãAïŒ10.5ã¶æ
ã»ã°ã«ãŒãBïŒ5.5ã¶æ
ã»ã°ã«ãŒãCïŒ6.4ã¶æ
ïŒå
šçåæéïŒOSïŒïŒ
ã»ã°ã«ãŒãAïŒ28.8ã¶æ
ã»ã°ã«ãŒãBïŒ21.7ã¶æ
ã»ã°ã«ãŒãCïŒ15.3ã¶æ
ãšãããããã°ã«ãŒãAã«å¯Ÿããã°ã«ãŒãBãCãææã«å£ãçµæãšãªããŸããã
ä»åã®ç ç©¶ã¯ãããããåŸæ¹èŠçãªéå»ã®çµæãæ¯ãè¿ã£ãŠã®ãã®ã§ããšããã³ã¹ã¬ãã«ãšããŠã¯èœã¡ãã®ã§ãããããã§ãããã ãã®å·®ãåºããšããããšã¯ããæ²»çã®é çªã®éãã¯æ²»çæçžŸã®å·®ãšããŠåºããå¯èœæ§ã匷ãæèããããåŸãŸããã
æ¬ããŒãïŒéºäŒåå€ç°ãã©ã®ã¿ã€ãã³ã°ã§èª¿ã¹ãã¹ããïŒã¯ãä»åŸãããæ²»çå
šäœã®äžã§éåžžã«éèŠãªè«ç¹ã§ããç¶ãããšæããŸãã®ã§ã远ããããŠåããŸãã
â»æ¬é
å·çæç¹ïŒ2024幎2æ15æ¥ïŒã§ãçè
ã¯éºäŒåããã«æ€æ»ã¡ãŒã«ãŒã®æ ªåŒãè¥å¹²æ°ä¿æããŠããŸãã
ââââââââââââââââââââââââââââââ
ããååãé¡ãïŒåæ²ïŒã 飿²»æ§ä¹³ããæ£è
ããããµããŒãããã€ã³ã¹ã¿ã¢ã«ãŠã³ãã®ãã©ããŒ
âââââââââââââââââââââââââââââââââââ
ããªãã«ãã¬ãã£ãä¹³ãããåçºãã€ãªã¹ã¯ä¹³ãããé²è¡ã»åçºä¹³ãããªã©ã®ã飿²»æ§ä¹³ãããã®æ£è
ããããµããŒããããã¢ãããŒãããšãããããžã§ã¯ãããããŸãã
ãã®ã¢ãããŒããšã®ãªã¢ãã»ãµã€ãšã³ã·ãºæ ªåŒäŒç€Ÿãå
±å¬ãã圢ã§ãã€ã³ã¹ã¿ã°ã©ã äžã§é£æ²»æ§ä¹³ããã®åçºãã£ã³ããŒã³ãæ¡åïŒãããïŒã€ã³ã¹ã¿ãã£ã³ããŒã³ããå§ãŸããŸããã
ãã¡ãã®ã€ã³ã¹ã¿ã°ã©ã ã®ã¢ã«ãŠã³ãããã©ããŒããããšã§ã
â¢é£æ²»æ§ä¹³ããã®æ£è
ããã®æ¥åžžç掻ã«ã€ããŠç¥ãããšãã§ãã
â¢é£æ²»æ§ä¹³ããæ£è
ããã®ããžãã£ããªæçš¿ãã¿ãŠå
æ°ããããã
ãšãã£ãããšãæåŸ
ã§ãããšã®ããšã
ã€ã³ã¹ã¿ã°ã©ã ã䜿ãããŠããæ¹ããã²åœè©²ã¢ã«ãŠã³ãããã©ããŒããŠããã ããã°å¹žãã§ããïŒã¢ã«ãŠã³ãã®ãã©ããŒã ãã§ãã®ã§ãç¹ã«ãéããããããšã¯ãããŸããïŒ
ãªããæ¬å
å®¹ã®æ²èŒã«ã€ããŸããŠãã®ãªã¢ãã»ãµã€ãšã³ã·ãºæ ªåŒäŒç€Ÿããåºåè²»ãããã ããŠããŸãã
ã€ã·ã¥ã©ã³ãå¥å
šãªåœ¢ã§ç¶ç¶ã»çºå±ãããŠããããã«ãç§ãä¿¡é Œã§ãããšå€æãããµãŒãã¹ãã¡ã«ãã¬äžã§ã玹ä»ãããã®å¯ŸäŸ¡ãäœããã®åœ¢ã§é ããšããä»çµã¿ãå°å
¥ããŠãããä»åã¯ãã®äžç°ã§ãã
äžèšã®è¶£æšããçè§£ããã ããå€ãã®çããŸã«ãååé ããŸããã幞ãã§ãã
ââââââââââââââââââââââââââââââ
ãèšäº2ãæè¥æºçæ²»çã¯è¡å§äœäžã«ã广ããïŒç±³åœçºã®ïŒæ¬ã®è«æ
âââââââââââââââââââââââââââââââââââ
æšå¹Ž12æã«çºè¡ããã¡ã«ãã¬ã§ããäžçåŸ
æã®ãã€ãšããè¬ãæ¥æ¬ã«ãç»å Žãä¿éºèšºçã®æ¯éã¯ïŒããšããèšäºãæžããŸããã
ãã®äžã§ããäœéãããŸãã³ã³ãããŒã«ã§ããã°ãç³å°¿ç
ã»é«è¡å§ã»é«èè¡ççã®ä»ã®çŸç
ã®æ²»çã«ãããè²»çšãå°æ¥çã«åæžã§ããå¯èœæ§ãé«ãã§ãããšæžããŸããããããããµããŒããããããªããŒã¿ãç«ãŠç¶ãã«åºãŠããŸããã
ãâ ââItâs a new eraâ: Weight-loss treatments significantly lower blood pressure, studies findâ
ãæ°æä»£ã ïŒæžéæ²»çãè¡å§ãææã«äœäžãããããšãç ç©¶ã§å€æãïŒCNNïŒ
äžèšã®CNNã®èšäºã§2æ¬ã®ç ç©¶çµæã玹ä»ãããŠããŸãã
1æ¬ç®ã¯ããã«ãŒããããšãããã¡ã«ãã¬å
ã§ç޹ä»ããã»ãã°ã«ããïŒãŠãŽãŒãïŒãšåããGLP-1å容äœäœåè¬ãšåŒã°ããçš®é¡ã®è¬ã®è©Šéšçµæã§ãã
BMIã27以äžããã€2åç³å°¿ç
ã§ã¯ãªããæ£åžžãªè¡å§ãããã¯æ²»çã«ããè¡å§ã³ã³ãããŒã«ãããŠãã600人ã§ããã«ãŒãããæäžåãšæäž9ã¶æåŸã®åçž®æè¡å§ïŒâäžâã®è¡å§ïŒãæ¯ã¹ããšããâŠ
ã»5mgæäžçŸ€ã¯ã7.4 mmHg
ã»10mgæäžçŸ€ã¯ã10.6 mmHg
ã»15mgæäžçŸ€ã¯ã8.0 mmHg
ã®è¡å§æžå°ãèŠãããŸããã
éå§å€1å€ã§äžããããè¡å§ã¯10-15mmHgçšåºŠãšèšãããŠããŸãã®ã§ããããŸã§ã¯ãããªãã«ãããããã¯åã°ããâå¯äœçšâãšèšããã§ãããã
ãã1æ¬ã¯ããæžéæè¡ãã«é¢ããç ç©¶ã§ãã
è¥æºçãã€é«è¡å§ã®æ£è
ãã100åãããæžéæè¡ïŒéå§å€æäžã矀ãšãéå§å€æäžã®ã¿ã矀ã«åãã5幎åŸã®çµéãèŠãŠäž¡è
ãæ¯èŒãããšããâŠ
ã»éå§å€ã®æäžæ°ãæžããããšãã§ãã人ã®å²åïŒ80% vs 14%
ããã«ããæžéæè¡ïŒéå§å€æäžã矀ã§é«è¡å§ãå¯è§£ãšãªã£ã人ãåæ°ããŸããã
ãšããããšã§ãnæ°ãå°ãªããããããŸã§ãã€ã¬ãã«ãªç ç©¶ã§ã¯ç¡ããšã¯ãããæžéæè¡ãè¡å§äœäžã«çµã³ã€ããŠããããšã䌺ããçµæã§ãã
è¥æºãšè¡å§ãšã®é¢ä¿ã¯ãç¥æžåŸªç°åšã¯ãªããã¯ãæžãããŠããããã°ãè¥æºã«ããé«è¡å§ãèµ·ããã¡ã«ããºã ãã«è©³ããã§ãã®ã§ãæ°ã«ãªãæ¹ã¯ãã§ãã¯ããŠã¿ãŠãã ããã
â»æ¬é
å·çæç¹ïŒ2024幎2æ15æ¥ïŒã§ãçè
ã¯ã»ãã°ã«ããããã«ãŒãããã«é¢é£ããç¹çãã¹ãå©ççžåã¯ãããŸããã
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒ
ããã®è©±ã«ã€ããŠã©ãæããæããŠæ¬²ããããšãããããªãèŠæãã¡ãŒã«ãã¬ãžã³ã®å
容ã«ã€ããŠã®ã質åããæèŠãè§£çŽã®ãåžæãªã©ã«ã€ããŸããŠã¯ãè¿ä¿¡ã®åœ¢ã§ãæ°è»œã«ã¡ãŒã«ããŠãã ããã
é
ä¿¡ããå
容ãšã¯ç¡é¢ä¿ã®è³ªåã§ãçµæ§ã§ããå¿
ããè¿äºããããŸãã ã¡ãŒã«ãã¬ãžã³ã®å
容ã®åŒçšã玹ä»ã転éããã©ãã©ããã£ãŠããã ããŠæ§ããŸããã
ã€ã·ã¥ã©ã³ã®æ°ãã詊ã¿ãšããŠããã以å€ã®çŸæ£ã§ãããç
é¢ã»å»åž«æ€çŽ¢ãµã€ããç®èããããäœã£ãŠãããŸãã
ã€ã·ã¥ã©ã³ãšåãããå®éã«å蚺ããæ£è
ããã®å£°ãã³ã³ãã³ããšãªã£ãŠããå
å®ãããµã€ãã«æé·ããŠãããŸãã®ã§ãèªè
ã®çããŸã«ããããŸããŠãããã²ãèªèº«ã®çµéšã«åºã¥ãããåç¥ã®ã¯ãªããã¯ãå
çã«ã€ããŠãæç¥š/æçš¿ããŠé ãããšå¬ããã§ãã
âç®èããã: https://hifunavi.ishuran.com/
ç®èãã ç®èã®çç¶ã§æ©ãããªãã®ç
é¢å»åž«æ€çŽ¢ãµã€ã
âSNSããã£ãŠããŸãããã²ãã©ããŒãããããé¡ãããããŸãã
ã»Facebookã¢ã«ãŠã³ãïŒhttps://www.facebook.com/ishuran.japan
ã»Twitterã¢ã«ãŠã³ãïŒhttps://twitter.com/ishuranjapan
ã»Instagramã¢ã«ãŠã³ãïŒhttps://www.instagram.com/ishuran_japan/
âã¡ã«ãã¬äŒå¡ïŒäŒå¡æ° â7â³äžäººïŒïŒ2023/12æç¹ïŒãžã®ç»é²ïŒç¡æïŒã¯ãã¡ãããâ
äŒå¡ç»é² ã€ã·ã¥ã©ã³ä¹³ãã(ä¹³ç) ç
é¢ã»å»åž«ã¬ã€ã
ä¹³ãã(ä¹³ç)ã§ãŸãå¿
èŠãªã®ã¯ãç
é¢ãå»åž«ãç確ã«ã¹ããŒãã£ã«éžã¶ããšãä¿¡é Œã§ããæ
å ±æäŸãããªã·ãŒã«ãç§åŠçæ ¹æ ã«ããšã¥ãæ€æ»ãæ²»çããããªã£ãŠããä¹³ããã®ç
é¢ãå»åž«ãäžèЧãªã¹ãã§ã玹ä»ããããªãã®åå»ããèŠã€ããŸãããã
ââââââââââââââââââââââââââââââ
ç§åŠçæ ¹æ ã«åºã¥ããªããäžè¬ã®æ¹ã«é¢çœãã»ãããæãå»çæ
å ±ãäŒããŸã
çºè¡ã»éå¶ãæ ªåŒäŒç€Ÿã¡ãã£ã«ã«ã»ã€ã³ãµã€ããéŽæšè±ä»
ââââââââââââââââââââââââââââââ